Breakthrough $20 million OCT project aims to revolutionize eye health screening

Some, though cer­tain­ly not all, chief in­di­ca­tors of biotech busi­ness ac­tiv­i­ty are point­ed shak­i­ly north as we head in­to a crit­i­cal Q4. But biotech shows

That was quick. One month af­ter Bris­tol My­ers Squibb com­plet­ed its $14 bil­lion ac­qui­si­tion of Karuna Ther­a­peu­tics, the CNS biotech’s ex­ec­u­tive and found­ing team are